Why are solid tumors so much harder to treat with CAR-T than blood cancers?
The central problem is that solid tumors create a hostile environment that actively shuts down CAR-T cells. Unlike blood cancers, where CAR-T cells can easily reach and kill cancer cells, solid tumors have a thick, immunosuppressive tumor microenvironment (TME) that blocks T-cell entry, saps their energy, and helps cancer cells hide. Multiple studies confirm this: reviews [1], [3], and [7] all highlight the TME as a primary obstacle, noting that it limits T-cell trafficking, infiltration, and persistence. For instance, one review explains that the TME is 'immunosuppressive' and that tumor antigens are highly heterogeneous, meaning not all cancer cells carry the same target, so CAR-T cells can miss entire subpopulations [1]. Another study found that even when CAR-T cells do get in, the tumor's acidity (from lactic acid buildup) suppresses their function [4]. This is why CAR-T has succeeded in blood cancers but failed in most solid tumor trials so far.
What new strategies are making CAR-T work in solid tumors?
Researchers are tackling the problem from multiple angles, and the evidence shows several promising approaches. One major strategy is to give CAR-T cells better 'homing' abilities. A 2026 study found that combining the chemokine CCL3 (which attracts T cells) with the survival cytokine IL-7 (which keeps them alive) produced a powerful synergy: CAR-T cells co-expressing both molecules showed significantly improved infiltration and longevity in solid tumors, leading to robust anti-tumor effects without systemic toxicity [6]. The study also showed this combination promoted the formation of tissue-resident memory T cells, which provide long-term protection. Another approach uses nanotechnology to deliver CAR genes directly into T cells inside the patient's body, bypassing the expensive, complex ex vivo manufacturing process. A review on mRNA-loaded lipid nanoparticles (LNPs) explains that this 'in vivo' engineering could turn the patient into their own cell therapy factory, drastically reducing cost and complexity [5]. A third strategy is to make CAR-T cells 'smarter' by engineering them to activate only in the tumor. One team created a lactic-acid-responsive promoter (LARP) that turns on CAR expression only in the acidic tumor microenvironment. In a mouse model, these LAR CAR-T cells achieved tumor eradication comparable to standard CAR-T cells but with 'significantly enhanced safety profiles,' including no acute liver toxicity and minimal off-target organ damage [4]. This is a direct example of precision medicine: the therapy activates only where it's needed.
What are the remaining obstacles, and can they be solved?
Despite the progress, significant challenges remain, and the evidence is honest about them. Antigen heterogeneity—the fact that not all tumor cells display the same target—is a major issue. One study found that even a promising target like CD70 is expressed at highly variable levels across tumor cells, from high to very low, and that conventional CAR-T cells can miss the low-expressing cells [8]. However, the same study showed that a more sensitive CAR design (called a HIT receptor) could eliminate these heterogeneous tumors that evaded standard CAR-T cells, suggesting that better receptor engineering can overcome this. Another study identified a new problem: when CAR-T cells attack, they release interferon-gamma (IFNγ), which can actually cause nearby cancer cells to lose the target antigen, a form of 'bystander antigen loss' [9]. The good news is that this effect could be reversed with drugs like JAK inhibitors or ER stress relievers, pointing to combination therapies as a solution. Finally, the issue of T-cell exhaustion is being addressed. A 2026 study showed that a 'clickable' strategy that artificially increases antigen density on tumor cells (by 5.7-fold compared to natural levels) actually reduced CAR-T cell exhaustion and improved function [2]. The authors note this strategy 'conferred remedial therapeutic efficacy' in patient-derived tumor models. So while the obstacles are real, the evidence shows that each one has a plausible engineering or combination-therapy solution in development.
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2024 to 2026, 9 from 2024 or later, 6 in Q1 journals, collectively cited 314 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 65 papers retrieved from a database of over 500 million.
Sources used in this answer
CAR-T therapy in solid tumors
This review discusses clinical advances and challenges for CAR-T in solid tumors, emphasizing antigen heterogeneity and the immunosuppressive TME, and suggests strategies like multi-targeting and combination with checkpoint inhibitors.
Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors.
The CUTE strategy uses metabolic glycoengineering to click exogenous antigens onto tumor cells, achieving 5.7-fold higher antigen density than natural CD19, which reduced CAR-T exhaustion and prolonged survival in patient-derived xenograft models.
Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors
This review highlights the potential of nanotechnology to address key challenges in CAR-T for solid tumors, including antigen heterogeneity, poor trafficking, and the immunosuppressive TME, aiming for more personalized therapy.
Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors.
A lactic-acid-responsive promoter (LARP) was engineered into HER2-targeting CAR-T cells; in a humanized mouse model, LAR CAR-T cells achieved tumor eradication comparable to conventional CAR-T but with no acute hepatotoxicity and minimal off-target toxicity.
In Vivo mRNA-Lipid Nanoparticle CAR-T Cell Engineering: Advances, Challenges, and Clinical Translation
This review synthesizes advances in mRNA-loaded lipid nanoparticles for in vivo CAR-T generation, noting that this approach eliminates leukapheresis and ex vivo culture, and discusses preclinical evidence in murine models and non-human primates.
CCL3 and IL-7 Synergistically Enhance CAR-T Efficacy in Solid Tumors.
CCL3 plus IL-7 synergistically improved CAR-T cell infiltration and longevity in solid tumors, promoting RUNX3 expression and CD69+CD103+ tissue-resident memory T cell differentiation, with robust anti-tumor efficacy and no systemic toxicity.
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
This review compares CAR-T and CAR-NK cells for solid tumors, noting that CAR-NK cells offer 'off-the-shelf' advantages and lower safety concerns but both face obstacles from limited trafficking and the immunosuppressive TME.
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
CD70 expression in solid tumors is epigenetically regulated and highly heterogeneous; a sensitive HIT receptor co-expressing CD80 and 4-1BBL eliminated CD70-heterogeneous tumors that evaded prototypic CAR-T cells.
IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy.
IFNγ secreted by activated CAR-T cells causes bystander colorectal cancer cells to lose the target antigen GUCY2C via JAK and ER stress pathways; this antigen loss can be rescued with anti-IFNγ antibody, ruxolitinib, or 4-phenylbutyrate.